Case Report: The First Case of Paradoxical Skin Lesions Induced by Xeligekimab in a Patient With SAPHO Syndrome

Key Points

• This case report aims to explore the unexpected occurrence of skin lesions due to Xeligekimab treatment in a SAPHO syndrome patient.
• Detailed clinical observation of the patient
• Assessment of skin lesions before and after Xeligekimab administration
• Documentation of the treatment course and response
• The patient developed paradoxical skin lesions following Xeligekimab treatment.
• Skin lesions appeared despite the intended therapeutic effect on SAPHO syndrome.
• This finding may indicate unique immunological responses to biologic therapies.